These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

452 related articles for article (PubMed ID: 27553599)

  • 41. Effects of chromium supplementation on glycemic control in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.
    Asbaghi O; Fatemeh N; Mahnaz RK; Ehsan G; Elham E; Behzad N; Damoon AL; Amirmansour AN
    Pharmacol Res; 2020 Nov; 161():105098. PubMed ID: 32730903
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pre-existing cardiovascular diseases and glycemic control in patients with type 2 diabetes mellitus in Europe: a matched cohort study.
    Fu AZ; Qiu Y; Radican L; Yin DD; Mavros P
    Cardiovasc Diabetol; 2010 Apr; 9():15. PubMed ID: 20409333
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Glycemic control in Kuwaiti diabetes patients treated with glucose-lowering medication.
    Abdullah A; Alkandari A; Longenecker JC; Devarajan S; Alkhatib A; Al-Wotayan R; Al-Duwairi Q; Tuomilehto J
    Prim Care Diabetes; 2020 Aug; 14(4):311-316. PubMed ID: 31911041
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Higher type 2 diabetes-related mortality when HbA1c levels are too low.
    Prescrire Int; 2008 Oct; 17(97):213. PubMed ID: 19536943
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Glycemic variability: adverse clinical outcomes and how to improve it?
    Zhou Z; Sun B; Huang S; Zhu C; Bian M
    Cardiovasc Diabetol; 2020 Jul; 19(1):102. PubMed ID: 32622354
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Intensified glucose control in type 2 diabetes--whose agenda?
    Yudkin JS; Richter B; Gale EA
    Lancet; 2011 Apr; 377(9773):1220-2. PubMed ID: 21093903
    [No Abstract]   [Full Text] [Related]  

  • 47. Indirect comparison of glucagon like peptide-1 receptor agonists regarding cardiovascular safety and mortality in patients with type 2 diabetes mellitus: network meta-analysis.
    Alfayez OM; Almohammed OA; Alkhezi OS; Almutairi AR; Al Yami MS
    Cardiovasc Diabetol; 2020 Jun; 19(1):96. PubMed ID: 32571416
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Noninsulin treatment of type 2 diabetes mellitus in geriatric patients: a review.
    Germino FW
    Clin Ther; 2011 Dec; 33(12):1868-82. PubMed ID: 22136979
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Issues surrounding tight glycemic control in people with type 2 diabetes mellitus.
    Cerveny JD; Leder RD; Weart CW
    Ann Pharmacother; 1998 Sep; 32(9):896-905. PubMed ID: 9762378
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Coronary microvascular dysfunction is associated with poor glycemic control amongst female diabetics with chest pain and non-obstructive coronary artery disease.
    Sara JD; Taher R; Kolluri N; Vella A; Lerman LO; Lerman A
    Cardiovasc Diabetol; 2019 Feb; 18(1):22. PubMed ID: 30819191
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Iixisenatide. Wait for conclusive results on complications of diabetes.
    Prescrire Int; 2014 Oct; 23(153):234-5. PubMed ID: 25964965
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Association between intensive glycemic control and mortality in elderly diabetic patients in the primary care: A retrospective cohort study.
    Ying DG; Ko SH; Li YC; Chen CX
    Prim Care Diabetes; 2020 Oct; 14(5):476-481. PubMed ID: 32291184
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes.
    Ratner R; Han J; Nicewarner D; Yushmanova I; Hoogwerf BJ; Shen L
    Cardiovasc Diabetol; 2011 Mar; 10():22. PubMed ID: 21410975
    [TBL] [Abstract][Full Text] [Related]  

  • 54. What matters in ADVANCE and ADVANCE-ON.
    Hamet P
    Diabetes Obes Metab; 2012 Jan; 14 Suppl 1():20-9. PubMed ID: 22118707
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Short-term intensive insulin therapy could be the preferred option for new onset Type 2 diabetes mellitus patients with HbA1c > 9.
    Weng J
    J Diabetes; 2017 Oct; 9(10):890-893. PubMed ID: 28661564
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Be Careful What You Ask For: Effects of Benefit Descriptions on Diabetes Patients' Benefit-Risk Tradeoff Preferences.
    von Arx LB; Johnson FR; Mørkbak MR; Kjær T
    Value Health; 2017 Apr; 20(4):670-678. PubMed ID: 28408010
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.
    Wang JS; Lin SD; Lee WJ; Su SL; Lee IT; Tu ST; Tseng YH; Lin SY; Sheu WH
    Clin Ther; 2011 Dec; 33(12):1932-42. PubMed ID: 22078152
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharm-MD; an open-label, randomized controlled, phase II study to evaluate the efficacy of a pharmacist-managed diabetes clinic in high-risk diabetes patients - study protocol for a randomized controlled trial.
    Halalau A; Shelden D; Keeney S; Hehar J
    Trials; 2018 Aug; 19(1):458. PubMed ID: 30143033
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Management of cardiovascular risk factors with pioglitazone combination therapies in type 2 diabetes: an observational cohort study.
    Rodríguez A; Reviriego J; Karamanos V; del Cañizo FJ; Vlachogiannis N; Drossinos V;
    Cardiovasc Diabetol; 2011 Feb; 10():18. PubMed ID: 21314919
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Glycated albumin versus glycated hemoglobin as glycemic indicator in hemodialysis patients with diabetes mellitus: variables that influence.
    Sany D; Elshahawy Y; Anwar W
    Saudi J Kidney Dis Transpl; 2013 Mar; 24(2):260-73. PubMed ID: 23538348
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.